We analyzed the short-term effects of one-time administration of evolocumab (PCSK9 inhibitor) on the lipid profiles (especially Lp(a)) and inflammatory markers in Korean patients with coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI). The gene discussed is PCSK9; the disease is coronary artery disorder.